Copenhagen-based digital therapeutics company Hedia has successfully raised €3 million in a seed extension funding round, with contributions from existing shareholders and business angels. This infusion of capital is set to propel Hedia’s growth strategy, enhancing its digital health product portfolio, particularly its Hedia Diabetes Assistant (HDA). Furthermore, the company is gearing up to launch a comprehensive diabetes management solution, integrated with Glooko, later this year. Hedia’s roadmap also includes the development of smart AI-enabled algorithms and Software-as-a-Medical Device (SaMD) solutions for chronic metabolic diseases, in collaboration with strategic partners.
The announcement coincides with the appointment of Lars Christian Lund as the new CEO. He expressed confidence in the team and technology, aiming to accelerate the commercialization of their solutions to improve the lives of people with diabetes.
Under the new leadership of CEO Lars Lund, Hedia aims to leverage its innovative technology and digital solutions to support individuals with insulin-dependent diabetes. Presently available in 11 countries, Hedia’s diabetes app is designed to offer personalized insulin recommendations, taking into account various aspects of diabetes management. These features include recording blood glucose readings, tracking active insulin, carb counting, insulin dosage calculation, activity monitoring, and blood ketone recording.
Hedia’s commitment to improving the lives of people with diabetes through digital innovation is evident in its growth and expansion plans. With the recent funding and strategic leadership, the company is well-positioned to accelerate the commercialization of its solutions and make a significant impact in the digital health sector, particularly in diabetes management.
